$102.51 -0.29 (%) Johnson & Johnson - NYSE

Feb. 27, 2015 | 04:00 PM

Partner Headlines

  1. Medivation Tops Q4 Views On Strong Xtandi Results

    IBD | Feb. 26, 2015 | 09:56AM EST
  2. Benzinga's M&A Chatter for Wednesday February 25, 2015

    Benzinga | Feb. 25, 2015 | 21:26PM EST
  3. Pharmacyclics hits new high

    IBD | Feb. 25, 2015 | 18:51PM EST
  4. Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'

    Benzinga | Feb. 25, 2015 | 17:05PM EST
  5. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD | Feb. 25, 2015 | 14:31PM EST
  6. Johnson & Johnson Has A Potential Buyer For Its Medical Devices Unit

    GuruFocus | Feb. 24, 2015 | 10:42AM EST
  7. 3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis

    Benzinga | Feb. 23, 2015 | 13:57PM EST
  8. Morgan Stanley Analyst Sees Higher Net For Cardinal Health In Johnson & Johnson Deal

    Benzinga | Feb. 23, 2015 | 11:45AM EST
  9. Johnson & Johnson: Why Investors Should Consider This Stock for Long-Term Gains

    GuruFocus | Feb. 22, 2015 | 19:00PM EST
  10. Can These Three BioTech Companies Make It Big?

    GuruFocus | Feb. 20, 2015 | 15:22PM EST
  11. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

    Benzinga | Feb. 20, 2015 | 13:10PM EST
  12. Paul Tudor Jones Is Betting on the SPY, Should You?

    GuruFocus | Feb. 20, 2015 | 13:05PM EST
  13. 10 Stocks Institutional Investors Loved Last Quarter

    Benzinga | Feb. 20, 2015 | 11:38AM EST
  14. Sterne Agee To Investors: Caution! Boston Scientific Priced To Perfection

    Benzinga | Feb. 20, 2015 | 09:08AM EST
  15. Medtronic Q3 Earnings 2015 Exceeds Market Expectations

    GuruFocus | Feb. 19, 2015 | 17:23PM EST
  16. Retirement ETFs To Look For

    GuruFocus | Feb. 19, 2015 | 12:58PM EST
  17. Boston Scientific Closes Up 12%

    Benzinga | Feb. 18, 2015 | 16:44PM EST
  18. Boston Scientific Soars 11% After Settling Dispute With Johnson & Johnson

    Benzinga | Feb. 18, 2015 | 14:42PM EST
  19. Mid-Day Market Update: Angie's List Jumps On Upbeat Earnings; MedAssets Shares Tumble

    Benzinga | Feb. 18, 2015 | 12:51PM EST
  20. Enphase Energy (ENPH) Record-Breaking Growth, Boston Scientific (BSX) and Johnson & Johnson ...

    GuruFocus | Feb. 18, 2015 | 11:36AM EST
  21. Sterne Agree Weighs In On Boston Scientific-Johnson & Johnson Litigation Settlement

    Benzinga | Feb. 18, 2015 | 10:24AM EST
  22. Stocks Hitting 52-Week Highs

    Benzinga | Feb. 18, 2015 | 10:05AM EST
  23. Morning Market Gainers

    Benzinga | Feb. 18, 2015 | 09:38AM EST
  24. Stock Futures Show Mild Losses; Boston Scientific Bolts Higher

    IBD | Feb. 18, 2015 | 09:16AM EST
  25. Benzinga's Top #PreMarket Gainers

    Benzinga | Feb. 18, 2015 | 08:11AM EST
  26. Fast Money Halftime Report Final Trade From February 17

    Benzinga | Feb. 17, 2015 | 17:50PM EST
  27. Johnson & Johnson's Strong Product Line-Up Makes It a Stock Worth Investing In

    GuruFocus | Feb. 17, 2015 | 12:10PM EST
  28. Johnson & Johnson Aiming To Bring A New Face to Medical Research

    GuruFocus | Feb. 16, 2015 | 12:10PM EST
  29. American Firms In China Feel Anti-Foreign Sentiment Rising In The Wake Of Qualcomm Settlement

    Benzinga | Feb. 13, 2015 | 14:25PM EST
  30. Bill Ackman Thinks Valeant Is 'Incredibly Disciplined,' And Says He'd Own McDonald's If 3G Capital Was In Charge

    Benzinga | Feb. 13, 2015 | 13:06PM EST
  31. Johnson & Johnson Faces Pressure From U.S. Patent Office

    Benzinga | Feb. 13, 2015 | 11:18AM EST
  32. Johnson & Johnson Under Selling Pressure

    Benzinga | Feb. 12, 2015 | 12:01PM EST
  33. High-Quality, Low-Risk Dividend Stocks

    GuruFocus | Feb. 10, 2015 | 14:00PM EST
  34. A Robust Q4 Earnings Report From Boston Scientific

    GuruFocus | Feb. 10, 2015 | 12:58PM EST
  35. Best Stock Picks For New Investors

    GuruFocus | Feb. 9, 2015 | 15:57PM EST
  36. Model Ophelia DeVore Stood Tall In Beauty Business

    IBD | Feb. 9, 2015 | 13:36PM EST
  37. Pfizer Buying Hospira To Inject Growth Into Generics

    IBD | Feb. 5, 2015 | 17:27PM EST
  38. Mallinckrodt's Mixed Q1 Stokes Analyst Worries

    IBD | Feb. 3, 2015 | 14:09PM EST
  39. Valeant Agrees To Buy Dendreon's Provenge

    IBD | Jan. 30, 2015 | 11:39AM EST
  40. ETF Spotlight: Dividend Aristocrat Index

    Benzinga | Jan. 29, 2015 | 14:58PM EST
  41. AmerisourceBergen Hits New High On Earnings, Outlook

    IBD | Jan. 28, 2015 | 13:45PM EST
  42. Are ETFs and CEFs Good Dividend Growth Investments?

    GuruFocus | Jan. 27, 2015 | 16:15PM EST
  43. Will Johnson & Johnson Continue Soaring?

    GuruFocus | Jan. 25, 2015 | 23:16PM EST
  44. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus | Jan. 23, 2015 | 16:13PM EST
  45. Johnson & Johnson's Strong Momentum Will Continue

    GuruFocus | Jan. 22, 2015 | 17:25PM EST
  46. Morgan Stanley Analyst Sees FY15 'Trough' For Johnson & Johnson Pharma Growth

    Benzinga | Jan. 22, 2015 | 11:54AM EST
  47. Covidien Q1 Earnings Beat Estimates As Buyout Nears

    IBD | Jan. 22, 2015 | 11:02AM EST
  48. Why Minerva Neurosciences Is Trading Higher

    Benzinga | Jan. 21, 2015 | 21:21PM EST
  49. Making Money With Charles Payne: 01/21/15

    FoxBusiness | Jan. 21, 2015 | 18:00PM EST
  50. Johnson and Johnson Beats Earnings Estimate, Slides On a Weak Outlook

    GuruFocus | Jan. 21, 2015 | 17:06PM EST
Trading Center